The ICER value framework describes the conceptual framework and set of associated methods that guide the development of ICER evidence reports. ICER typically updates the value assessment framework once every three years. The purpose of the value framework is to form the backbone of rigorous, transparent evidence reports that, as a basis for broader stakeholder and […]
The White Paper examines the efforts of payers to manage drug markups by implementing white bagging and brown bagging policies to shift the drug purchasing channel from providers to specialty pharmacies, as well as site of service policies requiring patients to receive treatment at lower-cost sites of care. The Paper examines the existing evidence and […]
ICER will will conduct our third annual assessment of how well major insurers’ prescription drug coverage policies align with a set of fair access standards developed by ICER with expert input from patient advocates, clinician specialty societies, US payers, pharmacy benefit managers, and life science companies. For each of the drugs reviewed by ICER in […]
The price of many existing drugs, both brand and generic, can increase substantially over time, and questions are frequently raised regarding whether these price increases are justified. State policymakers have been particularly active in seeking measures to address this issue. In 2019, we launched a new line of ICER reports, named Unsupported Price Increase (UPI) reports, […]
This paper illustrates how comparative effectiveness research can be used by policymakers and health insurers in California to address rising drug costs by aligning spending with the degree of benefit a treatment provides. ICER received a grant from the California Health Care Foundation (CHCF) to develop the White Paper. Date of publication: March 2023 For […]
ICER has received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide. Join us on March 21st for a webinar explaining […]
While many key elements of fair access were not able to be assessed, the analysis found that major payer coverage policies for 19 drugs demonstrated high concordance with many fair access criteria related to cost sharing, clinical eligibility, step therapy, and provider restrictions. During ICER’s assessment, five payers revised policies for 11 drugs in ways […]
This White Paper examines the potential risks and advantages of reforms to current policies related to orphan drug development, pricing, and coverage. The White Paper does not advocate for specific policy proposals. Instead, it analyzes the potential benefits and risks of reforms that might serve to reshape the incentives for orphan drug development in a […]
The price of many existing drugs, both brand and generic, can increase substantially over time, and questions are frequently raised regarding whether these price increases are justified. State policymakers have been particularly active in seeking measures to address this issue. In 2019, we launched a new line of ICER reports, named Unsupported Price Increase (UPI) reports, […]
This California Unsupported Price Increase final report is based on drugs identified through SB-17, the California drug price transparency law. ICER found that increases in spending for many drugs under the SB-17 law may be primarily due to increased volume rather than increases in net price. Final Documents ICER’s Chief Medical Officer David Rind, MD […]
Recent Comments